Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Value-Added Medicines

Set Alert for Value-Added Medicines

Medicines For Europe Highlights Sector Challenges As It Celebrates Milestone Anniversary

At Medicines for Europe’s 30th annual conference in Dublin last week, the European association and its Irish counterpart provided an overview of the challenges and opportunities facing the European off-patent industry.

Europe Policy

Outlook Sets Out Plans For Ophthalmic Bevacizumab In Europe

Outlook Therapeutics has revealed more details of its European launch strategy for its Lytenava ophthalmic bevacizumab following the product’s formal European Commission approval.

Approvals Launches

What’s Next? Five Things To Look Out For In June

Generics Bulletin previews the most noteworthy and anticipated events for June 2024.

Biosimilars Generic Drugs

Irish Body Calls For Urgent Action To Tackle Drug Shortages

Medicines for Ireland has called for action that would alleviate drug shortages affecting every fifth patient in the country after recently urging strategic reform in the EU.

Biosimilars Generic Drugs

Viatris Reveals Next Steps For Once-Monthly US Copaxone Rival After Rejection

Viatris has revealed the early stages of a battle plan after it was knocked back on US FDA approval for its proposed once-monthly glatiramer acetate ‘GA Depot’ product, a follow-on to Teva’s Copaxone treatment for relapsing forms of multiple sclerosis.

Strategy Sales & Earnings

A Year After ‘Pivot To Growth’, Teva Keeps Pushing Forward With Innovative Assets

Celebrating positive trial results for its long-acting injectable olanzapine, at the same time as reporting across-the-board growth for its generics business in Q1, Teva says it is pushing forward with its “pivot to growth” strategy almost a year after it was introduced by CEO Richard Francis.

Clinical Trials Strategy

Amneal Announces $272.5m Opioid Settlement Amid Positive Q1 Earnings

Amneal has joined the ranks of generics manufacturers who had to pay millions to settle legal claims linked to the sector’s alleged role in the US opioid epidemic.

United States BioPharmaceutical

Podcast: The Global Generics & Biosimilars Awards 2024

In a podcast discussion, Generics Bulletin’s editors talk about how you can enter and attend the Global Generics & Biosimilars Awards, what makes for a good entry, and why companies and individuals will want to get involved in the event.

Generic Drugs Biosimilars

What’s Next? Five Things To Look Out For In May

Generics Bulletin previews the most noteworthy and anticipated events for May 2024.

Generic Drugs Biosimilars

Amneal Launches Ready-To-Use Pemetrexed And OTC Naloxone

Amneal launched two highly anticipated products, a ready-to-use pemetrexed injectable Pemrydi and over-the-counter naloxone spray, strengthening the firm’s focus on injectables and inhalation.

United States Launches

Adalvo Hails First European Launch Of Prolonged-Release Pregabalin

After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.

Germany Value-Added Medicines

Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

Generic Drugs Biosimilars

Celltrion’s Subcutaneous Infliximab Lands On Big PBM Formulary List

One down, two more to go. Celltrion seals a formulary deal with one of the top three PBMs in the US for its subcutaneous infliximab product Zymfentra.

Strategy Biosimilars

Teva Pushes For Progress On Asthma Rescue Inhaler

Teva has struck a $150m strategic development funding agreement with Abingworth and a clinical collaboration agreement with Launch Therapeutics to accelerate development of a dual-action asthma rescue inhaler.

Deals Value-Added Medicines

What’s Next? Five Things To Look Out For In April

Generics Bulletin previews the most noteworthy and anticipated events for April 2024.

Biosimilars Generic Drugs

Hyloris Reports 44% Revenue Growth Driven By Royalties In 2023

Belgian company Hyloris Pharmaceuticals has reported a 44% revenue increase in its 2023 results while doubling down on its long-standing ambition to have 30 portfolio assets in the near future.

Sales & Earnings Strategy
See All
UsernamePublicRestriction

Register